Explore how pharmacists can support pancreatic cancer patients on atebimetinib as Immuneering leaders and oncologists discuss tolerability, education, and survival-focused phase 3 trial goals.
Sarah Cannon Research Institute | Strategic Alliance Partners
Latest from Sarah Cannon Research Institute
Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.
Explore the HER2CLIMB-05 study's findings on tucatinib's impact on breast cancer progression-free survival, enhancing treatment options for pharmacists.
Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.
Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5